What is Unjha Formulations share price return in the past 10 years?

Unjha Formulations Ltd share price has appreciated 21% annually (CAGR) over the past ten years.

Unjha Formulations Ltd - Stock Valuation and Financial Performance

Name: Unjha Formulations
Brand: Unjha Formulations

BSE: 531762 | NSE: | Pharmaceuticals & Drugs | Small Cap

Place order

Unjha Formulations Share Price

₹30.50 0.00 0.00%
as on 20-Dec'24 16:59

DeciZen - make an informed investing decision on Unjha Formulations

Based on:

Data

M-Cap below 100cr DeciZen not available

Unjha Formulations stock performance -

PE Chart Key Ratios

P/E Ratio (SA):

17.04

Market Cap:

13.7 Cr.

52-wk low:

14.9

52-wk high:

Is Unjha Formulations Ltd an attractive stock to invest in?

1. Is Unjha Formulations Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Unjha Formulations Ltd is a good quality company.

2. Is Unjha Formulations Ltd undervalued or overvalued?

The key valuation ratios of Unjha Formulations Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.

3. Is Unjha Formulations Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Unjha Formulations Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Unjha Formulations:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	68.7%	73.7%	67.6%	32.2%	25.4%	25.6%	26.8%	21.1%	16.8%	19.5%	-
Value Creation Index ⓘ	3.9	4.3	3.8	1.3	0.8	0.8	0.9	0.5	0.2	0.4	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	8.9	10.4	12.2	11.3	11.4	10.6	10	14.2	13.2	18.5	18
Sales YoY Gr.	-	16.1%	18%	-7.7%	1.1%	-7.2%	-6%	42.2%	-7.1%	40.7%	-
Adj EPS ⓘ	0.4	0.6	0.7	0.6	0.7	0.7	-0	0.3	0.6	0.6	1.8
YoY Gr.	-	46.2%	15.8%	-10.6%	13.6%	1.5%	-104.4%	NA	87.5%	3.3%	-
BVPS (₹) ⓘ	0.4	0.9	1.6	2.2	3.4	4.1	4.3	4.9	5.5	6.1	7.4
Adj Net Profit ⓘ	0.2	0.3	0.3	0.3	0.3	0.3	0	0.1	0.3	0.3	1
Cash Flow from Ops. ⓘ	-0.7	0.4	0.4	0.1	-0.1	0.4	-0.7	0.3	-0.3	1	-
Debt/CF from Ops. ⓘ	-0.6	0	0.1	0	0	0	0	0	0	0	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	8.4%	10.1%	22.9%	40.7%
Adj EPS ⓘ	5.3%	-1.5%	NA	3.3%
BVPSⓘ	37.4%	12.7%	12.5%	11.3%
Share Price	21%	30.1%	47.7%	93.2%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	57.2	49.5	37.1	24.4	22	18.4	-0.8	7	11.6	10.7	26.5
Op. Profit Mgn % ⓘ	2.1	3.5	3.1	3	2.6	2.3	3.7	2.3	3.3	3.1	6.3
Net Profit Mgn % ⓘ	2	2.5	2.4	2.3	2.6	2.9	-0.2	1	2	1.5	4.5
Debt to Equity ⓘ	2.5	0	0.1	0	0	0	0	0	0	0	0
Working Cap Days ⓘ	74	57	51	65	63	61	71	54	59	52	45
Cash Conv. Cycle ⓘ	-65	-40	-29	-36	-26	-13	2	13	23	19	21

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 26.50%

Sales growth is growing at healthy rate in last 3 years 22.92%

Sales growth is good in last 4 quarters at 28.26%

Net Profit has been subdued in last 3 years 0.00%

Latest Financials - Unjha Formulations Ltd.

	Standalone	Consolidated
TTM EPS (₹)	1.8	-
TTM Sales (₹ Cr.)	17.7	-
BVPS (₹.) ⓘ	7.4	-
Reserves (₹ Cr.) ⓘ	-1	-
P/BV ⓘ	4.12	-
PE ⓘ	17.04	-

From the Market
52 Week Low / High (₹)	14.85 / 39.00
All Time Low / High (₹)	1.00 / 39.00
Market Cap (₹ Cr.)	13.7
Equity (₹ Cr.)	4.5
Face Value (₹)	10
Industry PE ⓘ	44.3

Management X-Ray of Unjha Formulations:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Unjha Formulations

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Unjha Formulations

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	8.93	10.37	12.24	11.30	11.42	10.60	9.96	14.16	13.15	18.50
Operating Expenses ⓘ	8.75	10	11.86	10.95	11.12	10.35	9.59	13.84	12.72	17.92
Manufacturing Costs	1.27	1.36	1.82	1.54	1.90	1.94	1.86	2.27	1.03	1.20
Material Costs	6.43	7.67	9.11	8.51	7.83	7.36	6.73	10.48	10.45	15.28
Employee Cost	0.27	0.26	0.30	0.35	0.42	0.44	0.37	0.46	0.51	0.59
Other Costs ⓘ	0.77	0.71	0.64	0.56	0.97	0.61	0.63	0.63	0.72	0.85
Operating Profit ⓘ	0.19	0.36	0.38	0.34	0.30	0.25	0.36	0.32	0.43	0.58
Operating Profit Margin (%)	2.1%	3.5%	3.1%	3.0%	2.6%	2.3%	3.7%	2.3%	3.3%	3.1%
Other Income ⓘ	0.09	0.08	0.11	0.04	0.10	0.26	0.22	0.19	0.03	0.01
Interest ⓘ	0.01	0.10	0.10	0.02	0.01	0.12	0.17	0.13	0.06	0.05
Depreciation ⓘ	0.09	0.08	0.09	0.10	0.09	0.08	0.08	0.08	0.08	0.08
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Profit Before Tax ⓘ	0.17	0.26	0.30	0.26	0.30	0.31	0.33	0.30	0.33	0.45
Tax ⓘ	0	0	0	0	0	0	0.23	0.05	0.05	0.17
Profit After Tax	0.17	0.26	0.30	0.26	0.30	0.31	0.10	0.25	0.28	0.28
PAT Margin (%)	1.9%	2.5%	2.4%	2.3%	2.6%	2.9%	1.0%	1.8%	2.1%	1.5%
Adjusted EPS (₹)	0.4	0.6	0.7	0.6	0.7	0.7	0.2	0.6	0.6	0.6
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	0.39	0.65	0.94	1.21	1.51	1.81	1.92	2.17	2.45	2.73
Share Capital ⓘ	4.48	4.48	4.48	4.48	4.48	4.48	4.48	4.48	4.48	4.48
Reserves ⓘ	-4.09	-3.83	-3.54	-3.27	-2.97	-2.67	-2.56	-2.31	-2.03	-1.75
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	0.40	0	0.05	0	0	0	0	0	0	0
Long Term Debt	0	0	0.05	0	0	0	0	0	0	0
Short Term Debt	0.40	0	0	0	0	0	0	0	0	0
Trade Payables	2.51	2.28	2.79	2.75	2.10	1.86	1.60	1.25	0.94	2.04
Others Liabilities ⓘ	0	0	0	0	0.05	0.04	0.01	0.04	0.02	0.16
Total Liabilities ⓘ	3.30	2.93	3.78	3.96	3.65	3.72	3.53	3.45	3.41	4.93
Fixed Assets
Gross Block	3.67	3.70	3.98	4.02	4.06	4.16	4.23	4.25	4.35	4.46
Accumulated Depreciation	2.58	2.67	2.76	2.86	2.94	3.02	3.10	3.18	3.26	3.34
Net Fixed Assetsⓘ	1.09	1.03	1.22	1.16	1.12	1.14	1.12	1.07	1.10	1.12
CWIP ⓘ	0	0	0	0	0	0	0	0	0	0
Investmentsⓘ	0	0	0	0	0	0	0	0	0	0
Inventories	0.73	0.55	1.16	1.02	0.55	0.48	1.15	1.07	1.14	1.26
Trade Receivables	0.68	0.81	0.65	0.78	1.34	1.15	0.98	0.70	1.05	1.61
Cash Equivalents	0.20	0.19	0.34	0.49	0.65	0.94	0.17	0.43	0.01	0.87
Others Assetsⓘ	0.60	0.35	0.40	0.51	0	0	0.11	0.19	0.12	0.07
Total Assets ⓘ	3.30	2.93	3.78	3.96	3.65	3.72	3.53	3.45	3.41	4.93

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	-0.70	0.41	0.39	0.14	-0.12	0.39	-0.70	0.28	-0.26	1.03
PBT ⓘ	0.17	0.26	0.30	0.26	0.30	0.31	0.10	0.25	0.33	0.45
Adjustment ⓘ	0.11	0.19	0.19	0.12	0.10	0.20	0.25	0.21	0.13	0.13
Changes in Working Capital ⓘ	-0.97	0.07	0	-0.23	-0.51	0.01	-0.89	-0.05	-0.67	0.49
Tax Paid ⓘ	-0.01	0	0	0	0	0	0	0	-0.05	-0.05
Cash Flow From Investing Activity ⓘ	-0.09	-0.02	-0.28	0.06	0.04	-0.10	-0.06	-0.02	-0.10	-0.11
Capex	-0.09	-0.02	-0.28	0.06	0.04	-0.10	-0.06	-0.02	-0.10	-0.11
Net Investments	0	0	0	0	0	0	0	0	0	0
Others ⓘ	0	0	0	0	0	0	0	0	0	0
Cash Flow From Financing Activityⓘ	0.40	-0.40	0.05	-0.05	0.23	0	0	0	-0.06	-0.05
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	0	0	0.05	-0.05	0	0	0	0	0	0
Interest Paid ⓘ	0	0	0	0	0	0	0	0	-0.06	-0.05
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	0.40	-0.40	0	0	0.23	0	0	0	0	0
Net Cash Flow ⓘ	-0.38	-0.01	0.15	0.15	0.16	0.29	-0.77	0.26	-0.42	0.86

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	244.18	89.75	52.48	31.18	24.22	18.57	5.55	12.35	12.22	10.72
ROCE (%)	68.66	73.7	67.61	32.15	25.41	25.57	26.8	21.13	16.76	19.53
Asset Turnover Ratio	2.53	3.33	3.65	2.92	3	2.88	2.75	4.06	3.83	4.43
PAT to CFO Conversion(x)	-4.12	1.58	1.3	0.54	-0.4	1.26	-7	1.12	-0.93	3.68
Working Capital Days
Receivable Days	32	26	22	23	34	43	39	22	24	26
Inventory Days	29	23	26	35	25	18	30	29	31	24
Payable Days	172	114	101	119	113	98	94	50	38	36

Unjha Formulations Ltd Stock News

Unjha Formulations Ltd FAQs

What is the share price of Unjha Formulations?

Company share prices are keep on changing according to the market conditions. The closing price of Unjha Formulations on 20-Dec-2024 16:59 is ₹30.50.

What is the market cap of Unjha Formulations?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 20-Dec-2024 16:59 the market cap of Unjha Formulations stood at ₹13.67.

What is the P/E ratio of Unjha Formulations?

The latest P/E ratio of Unjha Formulations as of 20-Dec-2024 16:59 is 17.04.

What is the P/B ratio of Unjha Formulations?

The latest P/B ratio of Unjha Formulations as of 20-Dec-2024 16:59 is 4.12.

What is the 52-week high and low of Unjha Formulations?

The 52-week high of Unjha Formulations is ₹39.00 and the 52-week low is ₹14.85.

What is the TTM revenue of Unjha Formulations?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Unjha Formulations is ₹17.71 ( Cr.) .

About Unjha Formulations Ltd

Unjha Formulations (U-For), incorporated in 1987, is the sister concern of Urvesh Psyllium Industries Limited. U-For is the pharmaceuticals manufacturing unit, which is going to various category of formulation like tablet, capsule, oral liquids, injectables (SVP) and powder section to manufacture ayurvedic as well as allopathy products.

Fibron Powder & Fibron Sugar Free Powder are the branded ayurvedic products of the company, based on psyllium husk. The products met with an overwhelming success in our domestic market. The products mainly caters to somewhat sophisticated market segment who is conscious about their health and at the same time are very particular about various flavour like Orange, Lemon, Lime & Mango taste of the product.

Fibron Powder & Fibron SF powder offer excellent value for the money. Speed U - for could able to promote Fibron Powder & Fibron Powder SF at a most competitive price without sacrificing on quality mainly because their sister concern unit Urvesh Psyllium Industries Ltd. is one of the largest raw material supplier and processor of plyllium in the world. It may be important to note here that even Glaxo India Ltd, Proctor & Gamble, Nicholas Piramal India Ltd are the company's most valued costumers.

The company has entered into an agreement with Nicholas Piramal India for sale of Isabgol Husk based product `Tybogel` and Morepen Laboratories for sale of Dr.Mopren Sat Isabgol.

Urvesh Psyllium Industries Limited is the leading processor and exporter of Psyllium Husk & Powder in India.The company is in this line of business since last 52 years (i.e. from 1949). Initially it processed and supplied Psyllium products in local market but, looking to the worldwide demand, in 1966 it started to export Psyllium Products in the name of Rajendra Brothers. Later on with the increase of demand from overseas buyers there rose a need to expand the business, and thus Urvesh Psyllium Industries was formed in 1985, which later on was converted into a Limited Company in the year 1995.

Product range of the company includes: